234 related articles for article (PubMed ID: 25048483)
1. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
Lim YJ; Jung JW
Yonsei Med J; 2014 Sep; 55(5):1260-6. PubMed ID: 25048483
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease.
Jibiki T; Terai M; Kurosaki T; Nakajima H; Suzuki K; Inomata H; Terashima I; Honda T; Yasukawa K; Hamada H; Kohno Y
Eur J Pediatr; 2004 Apr; 163(4-5):229-33. PubMed ID: 14963702
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
4. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S; Kimura M; Ishikawa T; Ohzeki T
Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
Manlhiot C; Yeung RS; Chahal N; McCrindle BW
Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
[TBL] [Abstract][Full Text] [Related]
6. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
Inoue Y; Okada Y; Shinohara M; Kobayashi T; Kobayashi T; Tomomasa T; Takeuchi K; Morikawa A
J Pediatr; 2006 Sep; 149(3):336-341. PubMed ID: 16939743
[TBL] [Abstract][Full Text] [Related]
7. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
Nanishi E; Nishio H; Takada H; Yamamura K; Fukazawa M; Furuno K; Mizuno Y; Saigo K; Kadoya R; Ohbuchi N; Onoe Y; Yamashita H; Nakayama H; Hara T; Ohno T; Takahashi Y; Hatae K; Harada T; Shimose T; Kishimoto J; Ohga S; Hara T
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28684643
[TBL] [Abstract][Full Text] [Related]
8. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
9. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
[TBL] [Abstract][Full Text] [Related]
10. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
11. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.
Fukui S; Seki M; Minami T; Kotani K; Oka K; Yokomizo A; Matsubara D; Sato T; Nozaki Y; Saito M; Kikuchi Y; Miyamoto K; Monden Y; Yamagata T
Pediatr Rheumatol Online J; 2021 Jul; 19(1):107. PubMed ID: 34217297
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
Ogata S; Ogihara Y; Honda T; Kon S; Akiyama K; Ishii M
Pediatrics; 2012 Jan; 129(1):e17-23. PubMed ID: 22144699
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
Jibiki T; Kato I; Shiohama T; Abe K; Anzai S; Takeda N; Yamaguchi KI; Kanazawa M; Kurosaki T
Pediatr Int; 2011 Oct; 53(5):729-735. PubMed ID: 21342358
[TBL] [Abstract][Full Text] [Related]
16. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
[TBL] [Abstract][Full Text] [Related]
17. Role of glucocorticoids in Kawasaki disease.
Miura M
Int J Rheum Dis; 2018 Jan; 21(1):70-75. PubMed ID: 29105310
[TBL] [Abstract][Full Text] [Related]
18. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[TBL] [Abstract][Full Text] [Related]
19. Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.
Inoue T; Murakami S; Matsumoto K; Matsuda A
Pediatr Rheumatol Online J; 2020 Oct; 18(1):76. PubMed ID: 33023630
[TBL] [Abstract][Full Text] [Related]
20. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
